FibroGen (NASDAQ:FGEN) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(4.00) by 12.61 percent. This is a 17.65 percent increase over losses of $(4.25) per share from the same period last year. The company reported quarterly sales of $1.076 million which missed the analyst consensus estimate of $1.640 million by 34.39 percent. This is a 97.68 percent decrease over sales of $46.333 million the same period last year.